Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients

Psychosomatic Medicine

Volumn 65, Issue 4, 2003, Pages 571-581

  Carlson, Linda E ^a,b   Speca, Michael ^a,b   Patel, Kamala D ^b   Goodey, Eileen ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cancer; Cytokines; Lymphocytes; Meditation; Psychoneuroimmunology (PNI); Quality of life; Stress

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BREAST CANCER; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EDUCATION PROGRAM; FEMALE; HEALTH EDUCATION; HELPER CELL; HOME CARE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDITATION; MENTAL HEALTH; MENTAL STRESS; MINDFULNESS; MOOD; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOPHYSIOLOGY; QUALITY OF LIFE; RELAXATION TRAINING; SLEEP PARAMETERS; STRESS; YOGA;

ADENOCARCINOMA; AFFECT; AGED; ALCOHOL DRINKING; BREAST NEOPLASMS; CAFFEINE; CARCINOMA; CYTOKINES; DIET; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MEDITATION; MIDDLE AGED; NEUROIMMUNOMODULATION; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME; YOGA;

EID: 0041343198     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PSY.0000074003.35911.41     Document Type: Article

References (74)

1. Kabat-Zinn J. Full catastrophe living: using the wisdom of your body and mind to face stress, pain, and illness. New York: Delacourt; 1990.
2. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry 1982;4:33-42.
3. Kabat-Zinn J, Lipworth L, Burney R, Sellers W. Four-year follow-up of a meditation based program for the self-regulation of chronic pain: treatment outcomes and compliance. Clin J Pain 1986;2:159-73.
4. Kabat-Zinn J, Massion AO, Kristeller J, Peterson LG, Fletcher DE, Pbert L, Lenderking WR, Santorelli SF. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry 1992;149:936-43.
5. Miller JJ, Fletcher K, Kabat-Zinn J. Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. Gen Hosp Psychiatry 1995;17:192-200.
6. Kaplan KH, Goldenberg DL, Galvin-Nadeau M. The impact of a meditation-based stress reduction program on fibromyalgia. Gen Hosp Psychiatry 1993;15:284-9.
7. Singh BB, Berman BM, Hadhazy VA, Creamer P. A pilot study of cognitive behavioral therapy in fibromyalgia. Altern Ther Health Med 1998;4:67-70.
8. Deepak KK, Manchanda SK, Maheshwari MC. Meditation improves clinicoelectroencephalographic measures in drug-resistant epileptics. Biofeedback Self Regul 1994;19:25-40.
9. Kabat-Zinn J, Wheeler E, Light T, Skillings A, Scharf MJ, Cropley TG, Hosmer D, Bernhard JD. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med 1998;60:625-32.
10. Schneider RH, Staggers F, Alxander CN, Sheppard W, Rainforth M, Kondwani K, Smith S, King CG. A randomised controlled trial of stress reduction for hypertension in older African Americans. Hypertension 1995;26:820-7.
11. Reibel DK, Greeson JM, Brainard GC, Rosenzweig S. Mindfulness-based stress reduction and health-related quality of life in a heterogeneous patient population. Gen Hosp Psychiatry 2001;23:183-92.
12. Strain JJ. Adjustment disorders. In: Holland JF, editor. Psychooncology. New York: Oxford University Press; 1998. p. 509-17.
13. Derogatis LR, Morrow GR, Fetting J. The prevalence of psychiatric disorders among cancer patients. JAMA 1983;249:751-7.
14. Zabora JR, Blanchard CG, Smith ED, Roberts CS, Glajchen M, Sharp JM, Brintzenhofe-Szoc KM, Locher JW, Carr EW, Best-Castner S, Smith PM, Dozier-Hall D, Polinsky ML, Hedlund SC. Prevalence of psychological distress among cancer patients across the disease continuum. J Psychosoc Oncol 1997;15:73-86.
15. Cassileth BR, Chapman CC. Alternative and complementary cancer therapies. Cancer 1998;77:1026-34.
16. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-82.
17. Stewart DE, Cheung AM, Duff S, Wong F, McQuestion A, Cheng T, Purdy L, Bunston T. Attributions of cause and recurrence in long-term breast cancer survivors. Psychooncology 2001;10:179-83.
18. Carlson LE, Ursuliak Z, Goodey E, Angen M, Speca M. The effects of a mindfulness meditation based stress reduction program on mood and symptoms of stress in cancer outpatients: 6-month follow-up. Support Care Cancer 2001;9:112-23.
19. Speca M, Carlson LE, Goodey E, Angen M. A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med 2000;62:613-22.
20. Solberg EE, Halvorsen R, Sundgot-Borgen J, Ingjer F, Holen A. Meditation: a modulator of the immune response to physical stress? A brief report. Br J Sports Med 1995;29:255-7.
21. Taylor DN. Effects of a behavioral stress-management program on anxiety, mood, self-esteem, and T-cell count in HIV positive men. Psychol Rep 1995;76:451-7.
22. Ryu H, Jun CD, Lee BS, Choi BM, Kim HM, Chung HT. Effect of qigong training on proportions of T lymphocyte subsets in human peripheral blood. Am J Chin Med 1995;23:27-36.
23. Andersen BL, Kiecolt-Glaser JK, Glaser R. A biobehavioral model of cancer stress and disease course. Am Psychol 1994;49:389-404.
24. Levy SM, Herberman RB, Lippman M, D'Angelo T, Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med 1991;17:67-75.
25. Andersen BL, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum R, Courtney ME, Glaser R. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998;90:30-6.
26. Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, Fahey JL. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry 1990;47:729-35.
27. van der Pompe G, Duivenvoorden HJ, Antoni MH, Visser A, Heijnen CJ. Effectiveness of a short-term group psychotherapy program on endocrine and immune function in breast cancer patients: an exploratory study. J Psychosom Res 1997;42:453-66.
28. Richardson MA, Post-White J, Grimm EA, Moye LA, Singletary SE, Justice B. Coping, life attitudes, and immune responses to imagery and group support after breast cancer treatment. Altern Ther Health Med 1997;3:62-70.
29. Larson MR, Duberstein PR, Talbot NL, Caldwell C, Moynihan JA. A presurgical psychosocial intervention for breast cancer patients: psychological distress and the immune response. J Psychosom Res 2000;48:187-94.
30. Lekander M, Furst CJ, Rotstein S, Hursti TJ, Fredrikson M. Immune effects of relaxation during chemotherapy for ovarian cancer. Psychother Psychosom 1997;66:185-91.
31. Spiegel D, Sephton SE, Terr AI, Sittes DP. Effects of psychosocial treatment in prolonging cancer survival may be mediated by neuroimmune pathways. Ann N Y Acad Sci 1998;840:674-83.
32. Spiegel D, Sephton SE. Psychoneuroimmune and endocrine pathways in cancer: effects of stress and support. Semin Clin Neuropsychiatry 2001;6:252-65.
33. Garssen B, Goodkin K. On the role of immunological factors as mediators between psychosocial factors and cancer progression. Psychiatry Res 1999;85:51-61.
34. DeFlorio M, Masie MJ. Review of depression in cancer: gender differences. Depression 1995;3:66-80.
35. Keller M, Henrich G. Illness-related distress: does it mean the same for men and women? Acta Oncol 1999;38:747-55.
36. Riska E, Ettorre E. Mental distress: gender aspects of symptoms and coping. Acta Oncol 1999;38:757-61.
37. National Cancer Institute of Canada. Canadian Cancer Stats 2001. Toronto: National Cancer Institute of Canada; 2001.
38. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
39. Aaronson NK, Ahmedzai S, Bullinger M, Crabeels D, Estape J, Filiberti A, Flechtner H, Frick U, Hurny C, Kaasa S, Klee M, Mastilica M, Osoba D, Pfausler B, Razavi D, Rofe PB, Schraub S, Sullivan M, Takeda F. The EORTC core quality of life questionnaire: interim results of an international field study. In: Osoba D, editor. Effect of cancer on quality of life. London: CRC Press; 1991. p. 185-203.
40. McNair DA, Lorr M, Droppelman LF. Profile of mood states. San Diego: Educational and Industrial Testing Service; 1971.
41. Cassileth BR, Lusk EJ, Brown LL, Cross PA. Psychosocial status of cancer patients and next of kin: normative data from the profile of mood states. J Psychosoc Oncol 1985;3:99-105.
42. Leckie MS, Thompson E. Symptoms of stress inventory. Seattle: University of Washington; 1979.
43. Mendes R, Bromelow KV, Westby M, Galea-Lauri J, Smith IE, O'Brien ME, Souberbielle BE. Flow cytometric visualization of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood. Cytometry 2000;39:72-8.
44. Cohen J, Cohen P. Applied multiple regression/correlation analysis for the behavioral sciences. Hillsdale (NJ): Erlbaum; 1983.
45. Spiegel D. Cancer and depression. Br J Psychiatry Suppl 1996;(30): 109-16.
46. Speca M, Carlson LE, Goodey E, Angen M. A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med 2000;62:613-22.
47. Courneya KS. Exercise interventions during cancer treatment: biopsychosocial outcomes. Exerc Sport Sci Rev 2001;29:60-4.
48. Courneya KS, Friedenreich CM. Physical exercise and quality of life following cancer diagnosis: a literature review. Ann Behav Med 1999;21:171-9.
49. Friedenreich CM, Courneya KS, Bryant HE. Relation between intensity of physical activity and breast cancer risk reduction. Med Sci Sports Exerc 2001;33:1538-45.
50. Kiecolt-Glaser JK, Glaser R. Psychoneuroimmunology and cancer: fact or fiction? Eur J Cancer 1999;35:1603-7.
51. Dobbin JP, Harth M, McCain GA, Martin RA, Cousin K. Cytokine production and lymphocyte transformation during stress. Brain Behav Immun 1991;5:339-48.
52. Holden RJ, Pakula IS, Mooney PA. An immunological model connecting the pathogenesis of stress, depression, and carcinoma. Med Hypotheses 1998;51:309-14.
53. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998;25(1 Suppl 1):39-47.
54. Hauser P, Soler R, Reed S, Kane R, Gulati M, Khosla J, Kling MA, Valentine AD, Meyers CA. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000;41:439-41.
55. Capuron L, Ravaud A, Dantzer R. Early depressive symptoms in cancer patients receiving interleukin-2 and/or interferon-alfa-2b therapy. J Clin Oncol 2000;18:2143-51.
56. Tilg H, Atkins MB, Dinarello CA, Mier JW. Induction of circulating interleukin-10 by interleukin-1 and interleukin-2, but not interleukin-6 immunotherapy. Cytokine 1995;7:734-9.
57. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853-8.
58. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol 1995;41:534-8.
59. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K. Indicators of immune activation in major depression. Psychiatry Res 1996;64:161-7.
60. Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001;26:797-808.
61. Uchakin PN, Tobin B, Cubbage M, Marshall G Jr, Sams C. Immune responsiveness following academic stress in first-year medical students. J Interferon Cytokine Res 2001;21:687-94.
62. Kawamura N, Kim Y, Asukai N. Suppression of cellular immunity in men with a past history of posttraumatic stress disorder. Am J Psychiatry 2001;158:484-6.
63. Gooch JL, Lee AV, Yee D. Interleukin-4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 1998;58:4199-205.
64. Nagai S, Toi M. Interleukin-4 and breast cancer. Breast Cancer 2000;7:181-6.
65. Kawakami K, Kawakami M, Puri RK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol 2001;21:299-310.
66. Hernberg M. Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. Med Oncol 1999;16:145-53.
67. Nieman DC. Exercise immunology: practical applications. Int J Sports Med 1997;18(Suppl 1):S91-S100.
68. Woods JA, Davis JM, Smith JA, Nieman DC. Exercise and cellular innate immune function. Med Sci Sports Exerc 1999;31:57-66.
69. Spiegel D. Mind matters. Coping and cancer progression. J Psychosom Res 2001;50:287-90.
70. Geinitz H, Zimmermann FB, Stoll P, Thamm R, Kaffenberger W, Ansorg K, Keller M, Busch R, van Beuningen D, Molls M. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys 2001;51:691-8.
71. Beitsch P, Lotzova E, Hortobagyi G, Pollock R. Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery. Surg Oncol 1994;3:211-9.
72. Brenner BG, Margolese RG. The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer. Cancer 1991;68:482-8.
73. Grossarth-Maticek R, Eysenck HJ. Length of survival and lymphocyte percentage in women with mammary cancer as a function of psychotherapy. Psychol Rep 1989;65:315-21.
74. Michelson H, Bolund C, Nilsson B, Brandberg Y. Health-related quality of life measured by the EORTC QLQ-C30-reference values from a large sample of Swedish population. Acta Oncol 2000;39:477-84.